Loading...
Market
Gilead to sell generic HIV prevention injections in 120 countries by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Gilead and reports from health ministries in the target countries
Story
New HIV Prevention Injections Offer Six Months Protection; 100% Effective, Gilead to Sell Generics Ahead of World AIDS Day
Dec 1, 2024, 04:00 PM
Recent advancements in HIV prevention include long-acting injections that provide protection for up to six months per shot. As World AIDS Day approaches, experts are evaluating the implications of these new tools in combating HIV. A study has shown that a twice-yearly injection was 100% effective in preventing HIV infections among women and nearly as effective in men. Pharmaceutical company Gilead has announced plans to sell affordable generic versions of the medication in 120 countries with high rates of HIV. Despite these advancements, experts emphasize the importance of equitable access and addressing adherence challenges to maximize the impact of HIV prevention efforts.
View original story
Similar markets
No • 50%
Yes • 50%
No • 50%
Yes • 50%
More than 120 • 25%
81 to 120 • 25%
50 to 80 • 25%
Less than 50 • 25%
Novartis • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
South Africa • 25%
Other • 25%
UK • 25%
USA • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
Fewer than 30 countries • 25%
United States • 25%
Other • 25%
India • 25%
South Africa • 25%
Both equally • 25%
Neither dominates • 25%
Cabotegravir • 25%
Lenacapavir • 25%
Other • 25%
GlaxoSmithKline • 25%
AstraZeneca • 25%
Pfizer • 25%